In the present study, we assessed the impacts of various SNPs of CYP3A4, CYP3A5, and ABCB1 on clinical outcomes of a cohort of 103 patients who were given oral tacrolimus for the prevention of GVHD after allo-HSCT. The gene discussed is CYP3A4; the disease is graft versus host disease.